Business Wire

Softr Unveils an AI-Native Platform, Ushering in a New Era of Business Software Creation Without Code

31.3.2026 13:00:00 CEST | Business Wire | Press Release

Share

Softr today evolved into an AI-native platform, marking the end of the AI prototype era and the beginning of production-ready business software that non-technical teams can build, own, and maintain with AI — without writing a single line of code. With the introduction of its new AI Co-Builder, Softr enables teams to replace spreadsheets and manual workflows with secure, fully-functional business applications, including internal tools, customer portals, partner platforms, and operational systems, simply by describing what they need.

This milestone marks a major evolution for Softr, a leading player in the no-code software category over the past five years. Since launching in 2020, the company has grown to support more than 1 million builders and 7,000 organizations, including Netflix, Google, Stripe, UPS, and Clay.

Softr’s new platform was built to bridge the gap between AI-generated prototypes and software that can actually run business operations. Many AI app builders promise instant software from a single prompt, but stop at surface-level outputs, requiring users to manage code, fix errors, and rebuild workflows from scratch. Business software, on the other hand, runs on real data, connects to internal systems, and supports users with defined roles and permissions in real time — it has to work 100 percent of the time. When AI builders fall short or stop at the prototype, only a developer can fix it — resulting in months of work and hundreds of thousands of dollars to get software that should have been ready on day one. Softr closes that gap.

Softr’s new AI-native platform enables organizations to move from fragmented tools to fully operational software systems built in minutes — designed to run securely on live data, integrate with internal infrastructure, and provide structured access and governance from day one.

“For the first time, AI made the idea that ‘I can build something myself’ mainstream for millions of people — but most AI app-builders stop at the shiny demo stage,” said Mariam Hakobyan, Co-Founder and CEO of Softr. “We built Softr to solve the hard parts of software building. Every business app, from an internal HR portal to a client-facing tool, runs on real data, users, permissions, and security. It has to work every single time. Our goal has always been to give non-technical teams the ability to build the custom solutions they need without relying on developers. This evolution turns that vision into reality: software that helps people build and run the mission-critical software that powers their business operations.”

With the addition of Softr’s AI Co-Builder, users can describe the software they need in plain language, and the platform generates a fully integrated system — including the database, user interface, permissions, and business logic — connected and ready for real-world users immediately. Core foundations such as authentication, user roles, permissions, and hosting are built in from the start, eliminating the need for teams to configure or manage them separately.

Softr’s platform is built for business software that teams and customers can depend on every day. Each application is:

  • Secure and fully functional from day one, with built-in authentication and permissions
  • Powered by a visual, user-friendly database, giving users full control over their data
  • Built on custom workflows and integrations, ensuring systems work seamlessly across tools
  • Easy to maintain and evolve, without requiring code or repeated prompting

Teams use Softr to power critical workflows such as client portals, CRMs, company intranets, and operational systems across a wide range of industries. The company is now combining that profitable foundation with AI to accelerate its mission: to empower billions of business users to create production-ready software they can rely on from day one.

“The future of software isn’t written — it’s created,” Hakobyan added. “The next generation of software will be built by everyone — not because we simplified code, but because we simplified creation — and made building hard things easy.”

About Softr

Softr is the AI-native platform for building the software your business runs on—portals, internal tools, and operational systems—without code or developers. Describe what you need, and AI creates the database, app, and business logic—already connected, secure, and ready for real users. Over 1M+ organizations, from startups to enterprises like Netflix, Google, Stripe, UPS, and Clay, run their business operations on Softr-built apps. Visit softr.io to learn more.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260331754358/en/

Contacts

PR Contact
Kristin Lunt
softr@solcomms.co

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye